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Cell lines derived from human tumors have historically served
as the primary experimental model system for exploration
of tumor cell biology and pharmacology. Cell line studies,
however, must be interpreted in the context of artifacts intro-
duced by selection and establishment of cell lines in vitro.
This complication has led to difficulty in the extrapolation of
biology observed in cell lines to tumor biology in vivo. Mod-
ern genomic analysis tool like DNA microarrays and gene
expression profiling now provide a platform for the system-
atic characterization and classification of both cell lines and
tumor samples. Studies using clinical samples have begun to
identify classes of tumors that appear both biologically and
clinically unique as inferred from their distinctive patterns of
expressed genes. In this review, we explore the relationships
between patterns of gene expression in breast tumor derived
cell lines to those from clinical tumor specimens. This anal-
ysis demonstrates that cell lines and tumor samples have dis-
tinctive gene expression patterns in common and underscores
the need for careful assessment of the appropriateness of any
given cell line as a model for a given tumor subtype.
1. Introduction
Oncologists rely upon clinical information, a mor-
phologic assessment, and to a limited degree, immuno-
histochemical and molecular markers to classify ma-
lignancies into groups that have distinct clinical be-
havior. It is clear, however, that additional markers
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and/or technologies are needed for classifying tumors
as current methods sometimes fail to accurately predict
patient clinical course. In breast cancer for example,
tens to hundreds of different genes/proteins have been
shown to be of prognostic value, however, many of
these markers co-vary, and hence, are not of indepen-
dent prognostic value. In addition, progress in adopt-
ing these markers into clinical practice has been limited
both by technical constraints in the number of markers
that can be examined efficiently and by the difficulty
in comparing and validating studies that use different
reagents and clinical sample sets. In breast cancer, only
three markers are typically scored for in the clinical
setting which include the estrogen receptor (ER), the
tyrosine kinase receptor ERBB2/HER2, and an assess-
ment of tumor proliferation index (e.g. Ki-67 labeling
fraction) [1].
The advent of modern genomic analysis tools, in par-
ticular DNA microarrays, has essentially created a new
tool that is capable of collecting thousands of objec-
tive observations on clinical samples that can and are
being used to characterize tumors and cell lines at a
level of definition that was not possible even five years
ago [2]. Many groups have begun to use microarrays to
measure gene expression in hundreds of tumor samples
with the expectation that the genomic scale measure-
ment of gene expression will reveal a novel molecular
based classification of malignant cells. In this review,
we will first focus on the characterization of breast tis-
sue and tumor derived cell lines using data obtained
from cDNA microarrays. These data can be used to 1)
identify which cell lines are the best models for differ-
ent breast tumor subtypes, 2) define molecular signa-
tures that distinguish the biology of different cell lines
and tumor types, 3) identify new candidate markers
for tumor diagnosis and classification, and 4) identify
subtype specific targets for therapeutic intervention.
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Table 1
Cell line name Array # Previous description of cell line and (source)
184A1 svcc38 immortal derivative of 184Aa (M. Stampfer)
184Aa svcc17 primary HMEC strain Aa (M. Stampfer)
184B5 svcc40 immortal derivative of 184Aa (M. Stampfer)
BT-474-ATCC svcc128 ERBB2 and ER positive line (ATCC)
BT-474-Stanford svj107 ERBB2 and ER positive line (Stanford)
BT-549 svcc69 papillary/ductal carcinoma derived (NCI)
Fibroblast-UTSW shav146 hTERT immortalized stromal cell line (J. Shay/UTSW)
HB2 svcc37 SV40 immortalized breast epithelial line (H.S.Wiley)
HCC-1937 shaj046 BRCA1 mutant carcinoma derived line (J. Shay/UTSW)
HME31 shat023 primary HMEC strain 31 (J. Shay)
HMEC+IFNα svcc500 HMEC-C strain plus IFNα (Clonetics)
HMEC-C svcc94 primary HMEC strain C (Clonetics)
HMEC-C CON svcc47 HMEC-C strain 2 days at 100% confluence (Clonetics)
HMS32 shaj058 primary breast stromal/fibroblast cell strain (J. Shay)
Hs578T-ATCC shac095 breast carcinosarcoma derived line (ATCC)
Hs578T-NCI svcc110 breast carcinosarcoma derived line (NCI)
MCF-10A svn008 non-tumorigenic breast epithelial cell line (ATCC)
MCF-12A sham103 non-tumorigenic breast epithelial cell line (ATCC)
MCF7-NCI svcc1299 ER positive line isolated from a pleural effusion (NCI)
MCF7-UCLA shat022 ER positive line from a pleural effusion (UCLA)
MDA-MB-231-NCI svcc73 ER negative line from a pleural effusion (NCI)
MDA-MB-231-UTSW shaj054 ER negative line from a pleural effusion (J. Shay)
SK-BR-3 svcc15 ERBB2 positive line from a pleural effusion (ATCC)
T47D svcc71 ER positive line from a pleural effusion (ATCC)
2. Classification of breast cell lines
In general, cell lines established from breast tis-
sues have been mainly characterized with respect to
their expression of cytokeratins, the estrogen recep-
tor (ER), and ERBB2/HER2 protein [3–5]. For some
lines, the histology of xenografts has been compared
to the pathology of their tumor of origin in order to
confirm that the cell line has conserved features of its
parental tumor. As part of our efforts to characterize
the phenotypic diversity of human breast tumors, we
have measured gene expression using cDNA microar-
rays in a number of breast tissue derived cell lines [6–
8]. In this review, we have re-analyzed previously
published data from thirteen cell lines and report new
data from three additional independent lines. Further-
more, we explored cell line stability by measuring gene
expression in the same cell line obtained from differ-
ent sources and therefore propagated independently.
Lastly, we included some instructive data derived from
a normal mammary epithelial cell line treated with in-
terferon, data derived from a confluent normal cell line
culture, and a variant of a normal cell line immortal-
ized in vitro. Gene expression in these cell lines was
measured using spotted microarrays in comparison to
a common reference sample in a manner that has been
previously described and that allows all samples to be
compared to one another [6,7].
One of the most striking findings from genomic stud-
ies of gene expression to date has been that tumors
and/or cell lines have common characteristics of bio-
logical or clinical importance that can be identified in
their patterns of expressed genes. Hierarchical cluster-
ing analysis has been used to identify systematic fea-
tures in the patterns of variation of expression of genes
across sample sets [9–12]. The functions of the known
genes that are either relatively over-expressed or under-
expressed in comparison between samples can give
clues as to the differences in biology that are reflected
in gene expression patterns [6–8,13–16]. In this breast
cell line data set, we selected for analysis, the subset of
genes that showed 1) a signal intensity of >70 arbitrary
units in both the Cy3 and Cy5 channels, and 2) expres-
sion variation of at least 3-fold or more from average
for that gene across the sample set in two or more of
the 24 total experiments. This criterion selected 1287
genes out of the 8102 total original genes that were both
well measured and changed in expression significantly
between cell lines. All primary microarray data for
the experiments presented here can be obtained from
the Stanford Microarray Database at http://genome-
www4.stanford.edu/MicroArray/SMD/, and all figures
can be seen at our Supplementary Information web-
site at http://genome-www.stanford.edu/breast cancer/
cell line review2001/.
As can be seen in Fig. 1A, hierarchical cluster-
ing analysis divided the cell lines into three main
dendrogram branches. The first branch on the far
left (Red) contained all three of the primary Human
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Mammary Epithelial Cell (HMEC) lines, all HMEC
immortal derivatives and the non-tumorigenic MCF-
12A [17] cell line ostensibly derived from breast ep-
ithelium. The center dendrogram branch (Orange) con-
tained both normal fibroblast derived cell lines, a car-
cinosarcoma derived line (Hs578T [18]), a line osten-
sibly derived from breast epithelium (MCF-10A [19]),
and two lines derived from breast carcinoma specimens
(BT-549/Coutinho and Lasfargues 1978, and MDA-
MB-231 [20]). The far right dendrogram branch (Blue)
contained all cell lines that were thought to be de-
rived from luminal epithelial cells including two es-
trogen receptor expressing cell lines (MCF-7 [21] and
T47D [22]), two ERBB2 over-expressing lines (SK-
BR-3/Trempe and Old 1970, and BT-474 [23]), the
SV-40 transformed epithelial derived cell line HB2 [5],
and the BRCA1 mutant cell line HCC-1937 that was
originally isolated by A. Gazdar and colleagues [24].
The biological functions of the sets of genes that were
differentially expressed across different “branches” of
the cell line dendrogram (Fig. 1B–E) suggested that the
gene expression patterns identified cell lines with fea-
tures that could be related to different types of normal
breast cells. The cell lines sorted into those that ei-
ther expressed HMEC/basal-cell characteristics, those
that expressed stromal/mesenchymal-cell-like charac-
teristics or those that expressed luminal-cell character-
istics. It should be emphasized that this is an inter-
pretation of the gene expression patterns and that alter-
native interpretations of these gene expression patterns
are possible.
3. Breast basal epithelial cell signature
The group containing all HMEC lines (Red dendro-
gram branch) was distinguished by the very high ex-
pression of a set of genes that contained many mark-
ers of normal breast basal-epithelial cells including
keratins 5 and 17 (Fig. 1C) [3,4,25,26]. This set
also included many genes whose roles in cell phys-
iology distinguish basal from luminal epithelial cells
including the production of basal lamina components
and interactions with the extracellular matrix (e.g.
gamma and alpha-laminin, collagen type-XVII, inte-
grins alpha-3, alpha-6 and beta-4). The cultured basal-
like cell lines expressed variable amounts of smooth-
muscle-actin but much less relative to the other lines
that expressed the “stromal cell” gene expression sig-
nature (Fig. 1D). Therefore, these cultured cells ap-
peared to express some, but not all, of the features
of so-called “myo-epithelial cells” which are mature
smooth-muscle-actin expressing cells that have a func-
tional contractile apparatus [3,5,27]. This “basal” pat-
tern of gene expression was not restricted to HMEC
in that this set of genes were moderately expressed
in three other lines (MCF-10A, BT-549 and HB2)
that also expressed strong stromal-like gene expres-
sion signatures and therefore, did not fall into this
class by clustering analysis (see below). It should
also be noted that even immortal HMEC derivatives,
like 184B5 and 184A1, showed the dominant “basal”
cell gene expression pattern and not other signature
patterns, and hence, this pattern was not dramatically
influenced by immortalization or transformation (see
Supplementary Information Fig. 3 – http://genome-
www.stanford.edu/breast cell line review2001/).
4. Luminal epithelial cell signature
Approximately 60–70% of sporadic breast tumors
are estrogen receptor positive and are believed to be
derived from breast luminal epithelial cells [1], which
can be distinguished by their expression of cytokeratins
8 and 18 and by their location and function in lining
breast secretory-ducts. The in vitro study of this cell
type has been complicated by the difficulty in main-
taining primary cultures of normal estrogen-receptor-
positive luminal cells for longer than a few population
doublings [28]. Therefore, most in vitro studies on
breast luminal epithelial cells have been performed on
cell lines derived from primary breast tumors or pleural
effusions from breast cancer patients.
The pattern of gene expression that distinguished the
luminal-like signature was comprised of a set of genes
that were nearly exclusively expressed in all of the lu-
minal like lines while very low to absent levels were
seen in all of the other tested lines (Fig. 1E). Contained
within this set of genes were genes/proteins that have
been previously used to distinguish luminal breast ep-
ithelial cells including the estrogen receptor and ker-
atins 8 and 18 [3]. However, two distinct subtypes of
cell lines that expressed luminal characteristics could
be distinguished, 1) those that expressed high levels of
the estrogen receptor and essentially lacked either stro-
mal or basal gene expression signatures (e.g. MCF7,
BT-474 and T47D), and 2) those that expressed little
or no estrogen receptor but also expressed genes char-
acteristic of the basal signature (HCC-1937 and HB2).
SK-BR-3 was unique in this set of cell lines in that
it expressed low levels of the estrogen receptor but a
strong luminal gene expression signature without the
expression of basal cell characteristics.
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black = average expression
red = above average


















































































































Rho guanine nucleotide exchange factor GEF 5 AA001222 
ESTs AA074677 
hairless protein AA025648 
ESTs AA457707 
FXYD domain-containing ion transport regulator 3 AA126009 
cadherin 1, type 1, E-cadherin epithelial H97778 
cadherin 1, type 1, E-cadherin epithelial W86859 
N54395 
discoidin domain receptor family, member 1 H41900 
creatine kinase, mitochondrial 1 ubiquitous H43515 
creatine kinase, mitochondrial 1 ubiquitous AA019332 
nuclear factor I/A AA022462 
matriptase, epithin AA489246 
microtubule-associated protein 7 R77251 
junction plakoglobin R06417 
ladinin 1 T97710 
proline-rich Gla G-carboxyglutamic acid polypeptide 2 AA430552 
EphA1 N90246 
junctional adhesion molecule R81173 
CDP-diacylglycerol synthase phosphatidate cytidylyltransferase R31300 
ESTs N57927 
cDNA DKFZp564B1264 from clone DKFZp564B1264 AA453783 
ESTs R43675 
CD24 antigen small cell lung carcinoma cluster 4 antigen H59915 
EphB3 AA455591 
cDNA DKFZp564B1264 from clone DKFZp564B1264 AA046815 
inositol 1,4,5-trisphosphate 3-kinase isoenzyme N46828 
plexin B1 AA496565 
semaphorin 3F AA454570 
KIAA0429 gene product AA676805 
BTG family, member 2 H69582 
KIAA0599 protein T49575 
solute carrier family 31 copper transporters, member 2 R76281 
hypothetical protein FLJ10316 N33041 
Homo sapiens cDNA: FLJ22681 fis, clone HSI10693 AA464542 
carbonic anhydrase II H23187 
keratin 5 W72110 
stimulated trans-acting factor 50 kDa AA083407 
cystatin A stefin A W72207 
monoamine oxidase A AA011095 
interleukin 4 receptor AA292025 
keratin 17 AA026100 
keratin 17 AA159201 
ephrin-B1 AA428778 
laminin, gamma 2 AA677534 
matrix metalloproteinase 14 membrane-inserted N33214 
diacylglycerol kinase, alpha 80kD AA456830 
laminin, alpha 3 AA001431 
basonuclin R25330 
keratin 5 AA160507 
small proline-rich protein 1B cornifin AA447684 
collagen, type XVII, alpha 1 H87535 
bullous pemphigoid antigen 1 230/240kD H44784 
S100 calcium-binding protein A2 AA458884 
fatty acid binding protein 3 N70502 
annexin A8 AA235002 
insulin-like growth factor 2 somatomedin A H23457 
protein tyrosine phosphatase, receptor type, U AA644448 
integrin, beta 4 AA485668 
integrin, beta 4 AA076430 
KIAA0303 protein AA418846 
tubulin, alpha, ubiquitous AA453471 
ESTs W48579 
aspartate beta-hydroxylase W95682 
integrin, alpha 3 AA418994 
integrin, alpha 3 AA293040 
ESTs AA043551 
integrin, alpha 6 T54663 
integrin, alpha 6 H06635 
cyclin D2 H84153 
hypothetical protein FLJ22169 AA181288 
lysyl oxidase-like 2 AA676458 
DKFZP586E1621 protein AA125792 
microtubule-associated protein 1B AA219045 
corticotropin releasing hormone-binding protein AA286752 
connective tissue growth factor AA598794 
connective tissue growth factor AA044993 
transcription elongation factor B SIII AA128607 
vimentin AA147847 
vimentin AA486321 
insulin-like growth factor binding protein 7 T53297 
nectin 3; DKFZP566B0846 protein R62780 
ESTs, Highly similar to KIAA0379 protein [H.sapiens] N25798 
microtubule-associated protein, RP/EB family, member 2 AA608576 
tyrosyl-tRNA synthetase AA486761 
actin, alpha 2, smooth muscle, aorta AA040169 
actin, alpha 2, smooth muscle, aorta AA634006 
pregnancy specific beta-1-glycoprotein 6 T95747 
Thy-1 cell surface antigen AA428836 
disabled Drosophila homolog 2 H54577 
collagen, type V, alpha 1 R75635 
fibrillin 1 Marfan syndrome AA418674 
KDELendoplasmic reticulum protein retention receptor 3 AA181085 
COPZ2 for nonclathrin coat protein zeta-COP W70229 
contactin associated protein 1 AA028905 
platelet-derived growth factor receptor, beta R56211 
Sec23 S. cerevisiae homolog A AA406332 
collagen, type VI, alpha 2 AA633747 
platelet-derived growth factor receptor, alpha H23235 
collagen, type VI, alpha 2 AA464042 
Homo sapiens, alpha-1 VI collagen AA046525 
collagen, type VI, alpha 1 AA047208 
fibroblast growth factor 12B N71102 
collagen, type VI, alpha 3 R62603 
osteoblast specific factor 2 fasciclin I-like AA598653 
collagen, type III, alpha 1 Ehlers-Danlos syndrome type IV T98611 
collagen, type I, alpha 2 AA490172 
collagen, type III, alpha 1 Ehlers-Danlos syndrome type IV AA044829 
biglycan R77226 
ribosomal protein S3A N51018 
collagen, type I, alpha 1 W90359 
fibrillin 1 Marfan syndrome AA056415 
cadherin 2, type 1, N-cadherin neuronal W48793 
serine or cysteine proteinase inhibitor R71093 
microfibrillar-associated protein 4 AA442695 
activity-dependent neuroprotective protein N67071 
AE-binding protein 1 AA490462 
Homo sapiens cDNA FLJ12041 fis, clone HEMBB1001945 N40952 
uncoupling protein 2 mitochondrial, proton carrier H61242 
GTP cyclohydrolase I feedback regulatory protein AA074446 
ketohexokinase fructokinase T61256 
estrogen receptor 1 AA291702 
trefoil factor 3 intestinal N74131 
hypothetical protein LOC63931 T51290 
Homo sapiens cDNA: FLJ21278 fis, clone COL01832 T51229 
Homo sapiens cDNA FLJ13603 fis, clone PLACE1010270 W32933 
islet cell autoantigen 1 69kD AA482169 
lysosomal-associated membrane protein 1 H28973 
olfactomedin related ER localized protein H23123 
selenium binding protein 1 T65736 
bone morphogenetic protein 7 osteogenic protein 1 W73473 
fructose-1,6-bisphosphatase 1 AA699427 
N-acetyltransferase 1 arylamine N-acetyltransferase T67128 
similar to phosphatidylcholine transfer protein 2 R76229 
Homo sapiens cDNA: FLJ21587 fis, clone COL06946 R23610 
occludin H94471 
hypothetical protein FLJ22390 T61938 
hypothetical protein FLJ10120 R63971 
simian sarcoma viral v-sis oncogene homolog T49539 
claudin 7 AA487488 
epithelial membrane protein 2 T84249 
GTP cyclohydrolase 1 dopa-responsive dystonia AA443688 
keratin 18 AA070385 
keratin 18 AA664179 
transcription factor AP-2 gamma AA394236 
major histocompatibility complex, class I, A W92232 
CGI-111 protein T62691 
ESTs T69270 
ESTs, Weakly similar to K02E10.2 [C.elegans] T62552 
hepatocyte nuclear factor 3, alpha T74639 
hypothetical protein FLJ20150 W38021 
putative G protein-coupled receptor H50224 
solute carrier family 9 sodium/hydrogen exchanger 3 AA425299 
Human D9 splice variant B mRNA, complete cds AA453750 
KIAA0182 protein AI023801 
KIAA0182 protein H05099 
cation-chloride cotransporter-interacting protein AA037466 
putative neuroblastoma protein AA481950 
tumor-associated calcium signal transducer 1 AA055808 
claudin 4 AA427468 
E74-like factor 3 ets domain transcription factor AA433851 
E74-like factor 3 ets domain transcription factor H27938 
tumor protein D52 AA459100 
solute carrier family 29 nucleoside transporters 2 AA401361 
msh Drosophila homeo box homolog 2 AA194037 
grancalcin R19937 
keratin 8 AA598517 
keratin 8 AA069740 
cDNA DKFZp434C107 from clone DKFZp434C107 H06273 
partner of RAC1 arfaptin 2 AA425908 
neural precursor cell expressed, developmentally down-regulated 5 T39376 
Homo sapiens cDNA: FLJ21918 fis, clone HEP04006 T72068 
adaptor-related protein complex 1, gamma 2 subunit T49400 
keratin 19 AA464250 
fatty acid amide hydrolase AA431988 
envoplakin AA029418 
iroquois-class homeodomain protein R46202 
ESTs R55184 
Ts translation elongation factor, mitochondrial W47014 
GATA-binding protein 3 H72474 
GATA-binding protein 3 R31441 
palmitoyl-protein thioesterase 1 ceroid-lipofuscinosis AA034250 
ES1 zebrafish protein, human homolog of AA025421 
adenine phosphoribosyltransferase AA598510 
sulfotransferase family, cytosolic, 1A AA293695 
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Fig. 1. Cluster diagram depicting relative gene expression differences between cell lines. The red-green pseudocolor chart depicts gene expression
data in comparison between different cell lines. Red blocks depict genes relatively over-expressed in comparison between the measured samples
whereas green blocks depict genes relatively under-expressed. The data table has been organized by hierarchical clustering which groups the
genes on the basis of their similarity in expression patterns across a set of experimental samples (e.g. cell lines), and groups the experimental
samples together based upon their similarity in gene expression patterns across the set of chosen genes. The result of the analysis is a re-ordering
of the data table such that genes with relatively similar patterns of expression across the sample set are adjacent to one another in the rows, and
samples with similar patterns of expression in the set of chosen genes are adjacent to one another in the columns. The dendrogram above the
color chart depicts the relative similarities of the cell lines to one another; terminal branches contain cell lines that express relatively similar
patterns of gene expression across whereas those separated by longer branches express relatively less similar gene expression patterns [9]. A)
Complete cluster diagram that depicts all 1287 transcripts across 18 independent cell lines including 24 different hybridizations. B) “Common
epithelial” cell gene set that was expressed in both basal and luminal cells but was not expressed in the cells that have strong fibroblast-like
characteristics. C) Breast basal epithelial cell gene set that was strongly expressed in all HMEC derived cell lines. D) Stromal-like/fibroblast
gene set that was expressed in some fibroblasts as well as some breast cancer derived cell lines that were ostensibly mis-classified as carcinoma
derived. E) Luminal epithelial gene set that was expressed in estrogen-receptor-positive cell lines as well as a few other lines. The color scale at
the bottom left depicts the gene expression measured in each cell line relative to the average expression for each gene as determined in the 24
different cell line samples.
5. Mesenchymal/stromal cell signature
We have previously shown that a small, but signifi-
cant, number of cell lines ostensibly of epithelial ori-
gins showed patterns of gene expression that were more
consistent with characteristics expected of stromal cells
(see [6] and http://genome-www.stanford.edu/nci60/).
In order to further investigate the gene expression
properties of these cell lines we compared them to
two cell lines explicitly derived from breast stroma
(HMS32 and Fibroblast-UTSW, both obtained from
Jerry Shay/UTSW). The distinguishing gene expres-
sion signature for these strains/lines was comprised of
the high expression of a number of genes with roles in
remodeling of extracellular matrix including high ex-
pression of the genes encoding smooth muscle actin,
vimentin, fibrillin, byglycan and collagen types I, III,
V and VI (Fig. 1D), combined with the low expression
of genes characteristic of epithelial cells (Fig. 1B). The
cell lines contained within this branch of the dendro-
gram (Orange) were further subdivided into a branch
that contained three similar lines that expressed the
highest levels of this “stromal” gene expression signa-
ture and others that showed incrementally less expres-
sion of this set of genes. Consistent with the interpreta-
tion that this signature reflected expression of stromal
cell physiology, this signature was the most strongly
expressed in the carcinosarcoma derived line Hs578T
and the two cell lines/strains established from fibrob-
lasts, HMS32 (primary fibroblast strain with a finite
lifespan) and Fibroblast-UTSW (telomerase immortal-
ized breast derived fibroblast line). The remaining lines
that clustered with these fibroblast-like lines, showed
decreased overall expression of this set of genes with
incrementally less expression in BT-549, less in MCF-
10A, and finally, only a few stromal-signature genes
expressed in the two independently propagated lines of
MDA-MB-231 (Fig. 1D).
6. Common epithelial cell signature
In addition to the gene expression signatures that dis-
tinguished the three major branches of the cell line den-
drogram, both the basal-epithelial-like cell lines and
the luminal-epithelial-like cell lines expressed a set of
genes that were absent in those lines expressing the
stromal gene expression signature (Fig. 1B). This set
was comprised of many genes that play roles in cell-to-
cell contacts that seal the lumen or extracellular space
in epithelial tissues (e.g. E-cadherin, plakoglobin and
junctional-adhesion protein). This cluster likely distin-
guished genes involved in functions common between
subtypes of epithelial cells, and therefore, comprised a
molecular signature of epithelial cells (Fig. 1B).
7. Cell lines of ambiguous origins
Of particular interest were the breast derived cell
lines that lacked expression of the common epithelial
genes and expressed some characteristics of the “stro-
mal” expression signature including BT-549, MCF-
10A and MDA-MB-231. BT-549 showed strong ex-
pression of most of the genes in the stromal cluster
(Fig. 1D) and lacked expression of the other signature
expression patterns including the common epithelial
cell pattern. This suggests that BT-549 may represents
a myofibroblast-like line transformed in vitro or a line
like Hs578T that was originally derived from a stromal-
like tumor in vivo [18]. The MCF-10A [19] line is a
well-studied breast model system that expressed char-
acteristics of both the basal epithelial signature includ-
ing keratin expression, as well as genes that comprised
the stromal signature, but significantly, lacked expres-
sion of the common epithelial cell pattern. Perhaps the
most enigmatic cell line was MDA-MB-231 that did not
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show strong characteristics of any of the three signature
patterns of expression (Fig. 1C–E) except for a fraction
of genes that comprised the stromal cluster. This cell
line has been previously shown to be similar to renal
carcinoma derived cell lines in a separate study that
compared cell lines derived from a diverse set of tumor
types, and therefore, may represent a de-differentiated
cell type that has lost expression of the signature of its
tissue of origin [6]. Further gene expression studies
on these cell lines, including studies of their responses
to extracellular matrix stimuli, might distinguish their
potential for differentiation into cells with a more clear
relationship to their in vivo counterparts.
In a previous study, we shown that another cell line
that has been used as a model of aggressive-metastatic-
breast tumors, MDA-MB-435, showed a pattern of gene
expression that was very similar to the pattern seen
in seven independent melanoma derived cell lines (see
http://genome-www.stanford.edu/nci60/images/figure-
2c.html and [6]). This distinctive pattern included
strong expression of many genes characteristic of
melanocytes including tyrosinase, dopachrome tau-
tomerase and S100-β and therefore suggested that the
tested cell line was derived from a Melanoma and not
from a breast carcinoma. A number of different sam-
ples of MDA-MB-435 derived from different sources
showed a similar pattern suggesting that most, if not
all, examples of this cell line are similarly misclassified
(data not shown). These finding suggest that this cell
line is not an appropriate model system for the study of
breast carcinoma.
8. Breast tumor gene expression patterns
One of the most useful aspects of microarray tech-
nology is its utility in the study of gene expression pat-
terns in clinical tumor specimens [7,13,15,29–32]. We
have previously published a study of gene expression
profiles of forty breast cancer patients that included
twenty samples from patient’s tumors before and after a
sixteen week course of doxorubicin chemotherapy [7].
In order to identify the best set of genes to use for
tumor classification, we utilized a statistical approach
to identify the subset of genes that showed significant
variation in expression across different patients/tumors,
but which varied little in expression within paired sam-
ples from the same tumor [7]; this set of genes, termed
the “intrinsic” gene set, was enriched for those genes
whose expression patterns were characteristic of each
tumor as opposed to those that varied as a function of
sampling error. An example of a gene that showed this
“intrinsic” property was ERBB2/HER2, which was ex-
pressed at high levels in some tumors and not others
(forty-fold difference within this sample set), but which
was consistent in expression in comparison between
multiple samples taken from the same tumor.
Hierarchical clustering analysis using this “intrin-
sic” gene set of 476 cDNA clones (including 426 dif-
ferent genes) resulted in a novel molecular classifica-
tion of the tumor samples on the basis of gene ex-
pression patterns (see Fig. 2 of [7] at http://genome-
www.stanford.edu/molecularportraits/images/figure2.
html). Importantly, the tumor samples cluster dendro-
gram from this analysis showed that the repeat biop-
sies taken from the same patient (i.e. the 20 “before”
and “after” doxorubicin sample pairs) were found to
almost always be more similar to each other than ei-
ther was to any of the other tumors tested (17/20 “be-
fore” and “after” pairs were paired and 2/2 tumor/lymph
node metastasis pairs were paired). This implied that
every tumor is unique and has a distinctive gene ex-
pression “signature” or “portrait”. These gene expres-
sion patterns distinguished four discrete tumor subtypes
that, similar to the cell line studies, could be related
to features of normal breast cell type in vivo. The
classes of tumor subtypes identified were 1) a “lumi-
nal epithelial/ER+” subtype that was distinguished by
high expression of a set of approximately twenty genes
that included the ER gene and other genes known to
be regulated by estrogen, 2) a normal breast-like group
of samples that contained the three normal breast sam-
ples, a single fibroadenoma and 5 tumor samples, 3) a
group of tumors most of which expressed high levels
of the ERBB2/HER2 gene, and 4) a group of tumors
that had gene expression patterns reminiscent of breast
basal epithelial cells.
Building upon these studies, we recently reported
gene expression patterns of an expanded set of 78 dif-
ferent breast tumors [33]. Cluster analysis of data
derived from this larger tumor set re-identified the
same four tumor subtypes in addition to one addi-
tional subclass of ER+ tumors, such that five sub-
types were now distinguished. To explore whether
this classification of breast tumors was clinically sig-
nificant, we assigned each of the 51 tumors that com-
prised the cohort of “before” and “after” doxoru-
bicin patients [34], to a class based upon its location
within the tumor sample associated dendrogram and
did Kaplan-Meier survival analysis (see http://genome-
www.stanford.edu/mopo/clinical/ and [33]). We found
that these subtypes, as defined by gene expression pat-
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terns, had statistically significant different overall pa-
tient survival and relapse free survival characteristics.
The luminal/ER+ positive patients were sub-divided
into two classes of which a novel subtype was identi-
fied (Luminal B/C) that had a significantly worse out-
come when compared to the rest of the ER+ tumors
(Luminal A), which showed the most favorable out-
comes. Furthermore, the set of patients classified as
“basal-like” had outcomes as poor as those that over-
expressed ERBB2/HER2. The patterns of gene expres-
sion that were distinguished in these studies represent
novel molecular signatures of breast tumors that can
be used to 1) develop new clinical tests based upon
gene expression patterns to score for these subtypes,
2) identify candidate markers for diagnosis, 3) iden-
tify genes important for understanding the biology that
distinguishes basal and luminal epithelial cells, and 4)
identify subtype specific targets for developing thera-
peutic interventions.
9. An integrated cell line and breast tumor analysis
The set of genes that defined epithelial cell character-
istics within the cell line panel was remarkably similar
to the set of genes that distinguished tumor subtypes
amongst the breast carcinomas. This suggested that
certain cell lines may be very good models for specific
subtypes of tumors. In order to more directly compare
and contrast primary breast tumors and cell lines, we
created a single hierarchical clustering diagram using
the aforementioned “intrinsic” gene list and data from
16 cell lines discussed above and our previously pub-
lished study on 40 breast tumors and three normal breast
samples (Fig. 2, and see Supplementary Information
Fig. 4 for the complete cluster diagram – http://genome-
www.stanford.edu/breast cancer/cell line review2001/).
As expected, the results showed a similar grouping of
the tumors samples into at least four subtypes including
luminal/ER+ (dark blue), ERBB2/HER2+ (pink), nor-
mal breast-like (green), and a basal-like classes (dark
red). The cell lines, regardless of their presumed cell-
type of origin, clustered together on a single large
dendrogram branch separate from all of the tumors,
however, they were also similarly subdivided into the
basal, luminal, and stromal-like groups described above
(Fig. 2).
The luminal/ER+ signature was most strongly ex-
pressed in a large group of ER expressing tumors
and the subset of cell lines that expressed the lumi-
nal gene expression signature (blue dendrogram branch
and Fig. 2B). The pattern of expression of this set of
genes showed both quantitative and qualitative differ-
ences between the luminal/ER+ tumors in compari-
son to the luminal cell lines. These tumor samples
were comprised of at most 60–70% tumor cells, but
expressed stronger and more consistent levels of this
gene set when compared to the “pure” population of
cell derived from a single cell line. Given the diffi-
culty in establishing cultures from cells expressing lu-
minal characteristics, the loss of expression of these
genes may be related to the process of establishment
or maintenance of cell lines in vitro. It was interesting
that the ERBB2+ tumor subtype expressed fewer of
these genes than the luminal-like/ER+ tumors, and in
most cases, expression levels lower than the luminal
cell lines. These patterns were consistent with the no-
tion that the relative level of expression of this set of
genes may reflected the degree of luminal differentia-
tion of the tumor samples. Taken together, these re-
sults suggested that the best models for ER+ luminal
epithelial cell derived tumors, choosing from the cell
lines tested here, are MCF7, T47D and BT-474, with
SK-BR-3 serving as a model of luminal-cell derived
ER-negative/ERBB2 positive tumors.
We have previously shown that most of the genes
highly expressed in a pattern similar to ERBB2 across
large sets of breast tumors are all part of the co-
amplified chromosomal region that contains ERBB2 [7,
35–38]. In this analysis, most of the tumors that ex-
pressed this gene expression signature as their pri-
mary distinguishing characteristic were clustered to-
gether and formed a discreet subtype (pink dendro-
gram branch, and Fig. 2D). A few other tumors that
expressed the ERBB2 signature were present, however,
they also expressed either the luminal or normal breast
signatures and were clustered based upon those distin-
guishing characteristics. Both BT-474 and SK-BR-3
showed high level expression of the ERBB2 signature
and therefore are likely appropriate cell line models for
ER-positive and ER-negative, ERBB2 over-expressing
tumors, respectively.
The basal-like tumors were distinguished by strong
expression of keratin 5 and 17 relative to the luminal
cell-like tumors (Fig. 2 and [7]). The basal epithelial
gene expression signature expressed by HMEC lines
was in part expressed by both the basal-like tumors and
normal breast tissue, which appeared to be comprised
predominantly of basal epithelial cells (dark red den-
drogram branch and Fig. 2E). These results suggested
that the basal like cell lines/HMEC cultures and their
derivatives, are in general, appropriate model systems
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black = average expression
red = above average
















































































































































































































































































































































































































































































































































complement component 4A AA664406 
KIAA0182 protein AI023801 
fatty acid amide hydrolase AA431988 
major histocompatibility complex, class I, A W92232 
ESTs AA029948 
B/K protein H23265 
cellular retinoic acid-binding protein 2 AA598508 
cellular retinoic acid-binding protein 2 AA036986 
claudin 7 AA487488 
tumor protein D52 AA459100 
hypothetical protein FLJ20150 W38021 
vav 3 oncogene W91879 
mucin 1, transmembrane AA486365 
KIAA1223 protein R72441 
nebulette N77806 
ESTS similar to transcription factor forkhead-like 7 FKHL7 AA495790 
ras homolog gene family, member B H88963 
cytochrome b-5 R91950 
annexin A9 N54608 
estrogen receptor 1 AA291702 
trefoil factor 3 intestinal N74131 
GATA-binding protein 3 H72474 
GATA-binding protein 3 R31441 
X-box binding protein 1 W90128 
hepatocyte nuclear factor 3, alpha T74639 
putative G protein-coupled receptor H50224 
selenium binding protein 1 T65736 
Homo sapiens cDNA FLJ11408 fis, clone HEMBA1000822 H53479 
Human insulin-like growth factor binding protein 5 IGFBP5 T52829 
Human insulin-like growth factor binding protein 5 IGFBP5 AA054451 
Human insulin-like growth factor binding protein 5 IGFBP5 H08560 
ESTs, Weakly similar to macrophage lectin 2 [H.sapiens] N53421 
Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321 N69835 
Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321 R98407 
DKFZP586O1624 protein AA159578 
hepsin transmembrane protease, serine 1 H62162 
EST similar to transcription elongation factor TFIIS R09980 
trefoil factor 1 breast cancer, estrogen-inducible in R83377 
ESTs W87826 
cDNA: FLJ21918 fis, clone HEP04006 T72068 
serine protease inhibitor, Kunitz type, 2 AA031287 
cadherin 1, type 1, E-cadherin epithelial W86859 
cadherin 1, type 1, E-cadherin epithelial H97778 
junction plakoglobin R06417 
creatine kinase, mitochondrial 1 ubiquitous H43515 
nuclear factor I/A AA022462 
creatine kinase, mitochondrial 1 ubiquitous AA019332 
metargidin AA292676 
myeloid/lymphoid or mixed-lineage leukemia trithorax homolog AA454610 
zinc finger protein 144 Mel-18 AA464420 
cDNA DKFZp564O2364 from clone DKFZp564O2364 W90240 
matrix metalloproteinase 15 membrane-inserted AA443300 
SWI/SNF related, matrix associated, subfamily e, member 1 W51779 
ESTs T57034 
TNF receptor-associated factor 4 AA598826 
TGFB1-induced anti-apoptotic factor 1 AA446222 
hypothetical protein FLJ10700 W81185 
flotillin 2 R72913 
steroidogenic acute regulatory protein related AA504615 




KIAA0130 gene product N54470 
Human proteinase activated receptor-2 AA454652 
pre-B-cell colony-enhancing factor AA281932 
v-myc avian myelocytomatosis viral oncogene homolog AA464600 
ESTs, Highly similar to JE0164 frizzled-6 protein T68333 
metallothionein 1L N80129 
metallothionein 1G H53339 
integrin, alpha 2 AA463257 
integrin, alpha 2 AA069027 
GRO1 oncogene, alpha W42723 
secretory leukocyte protease inhibitor antileukoproteinase AA026192 
hypothetical protein FLJ20481 N32611 
caveolin 1, caveolae protein, 22kD AA055368 
caveolin 2 T84152 
annexin A1 H63077 
insulin-like growth factor binding protein 6 AA478724 
troponin I, skeletal, fast AA181334 
ESTs AI679149 
integrin, beta 4 AA076430 
laminin, gamma 2 AA677534 
matrix metalloproteinase 14 membrane-inserted N33214 
laminin, alpha 3 AA001431 
collagen, type XVII, alpha 1 H87535 
bullous pemphigoid antigen 1 230/240kD H44784 
ataxia-telangiectasia group D-associated protein AA055485 
keratin 17 AA026100 
keratin 5 W72110 
muscle and heart mammary-derived growth inhibitor N70502 
cadherin 3, type 1, P-cadherin placental AA425217 
epidermal growth factor receptor AA234715 
ESTs, Highly similar to T2EA W37448 
transforming growth factor, beta receptor II AA487034 
Unknown Clone 1
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Fig. 2. Integrated analysis of breast tumors and cell lines using the “intrinsic” gene set. Cluster diagram (see legend to figure 1) depicting the
relationships between gene expression patterns in breast cancer derived cell lines and tumor specimens. A) Experimental sample associated
dendrogram showing distinct tumor and cell line subtypes. B) Luminal/ER+ gene expression cluster. C) Common epithelial cell cluster
containing E-cadherin. D) ERBB2+ amplicon cluster. E) Basal epithelial cell cluster. The color scale at the top right depicts the gene expression
measured in each sample relative to the average expression for each gene as determined in the 87 different samples. The full microarray data files
for all 87 experiments can be obtained from the Stanford Microarray Database at http://genome-www4.stanford.edu/MicroArray/SMD/, and the
full cluster diagrams for Figs 1 and 2 can be seen at http://genome-www.stanford.edu/breast cancer/cell line review2001/.
for the breast basal-like tumors. The absence of expres-
sion of any genes characteristic of the luminal signature
suggests that HMEC cultures and their derivatives are
NOT appropriate models of hormone responsive breast
tumors, which comprise the majority of sporadic breast
tumors [1]. HB2 and HCC-1937, as noted above, ex-
pressed genes characteristic of both the basal and lumi-
nal signatures, and therefore may be similar to basal-
like tumors that often co-express cytokeratin 17 and 18
in vivo (M. van de Rijn, personal communication).
The cell lines that expressed the stromal cell signa-
ture (orange dendrogram branch), with the exception
of MCF-10A, showed very few gene expression char-
acteristics in common with any of the breast tumors,
even those that were highly metastatic when sampled
for microarray analysis. The cellular origins of these
cell lines are still enigmatic and it is not clear which,
if any, of these cell lines are appropriate models for
breast carcinoma. It is interesting to note, however,
that some of the cell lines contained within this clus-
ter, in particular MDA-MB-231, are some of the most
tumorigenic and aggressive in nude mouse xenograft
models [39]. Most interesting amongst these cell lines
was MCF-10A, which expressed some genes character-
istic of basal like tumors including keratin expression,
but lacked expression of the common epithelial signa-
ture. Interestingly, this cell line is not tumorigenic in
xenograft models.
10. Summary
The advent of the DNA microarray technology has
enabled researchers to measure genomic scale gene ex-
pression in human cancers and cell lines. The explo-
ration of these gene expression patterns is challeng-
ing oncologists and pathologists to re-assess traditional
classifications of cancer and incorporate molecular fea-
tures into treatment regimens and drug development
strategies. The great strength of cDNA microarray
studies coupled to hierarchical clustering analysis is
the ability to objectively identify sets of coordinately
expressed genes and display the data in a format that a
biologist can utilize to form hypotheses.
The data presented here, and in our previous studies,
have shown that many different gene selection criteria,
across different sets of breast tumors and cell lines, con-
sistently identified similar sets of genes that can serve
as markers for probing the biology of breast cancer [6,
7,33]. The comparison of gene expression patterns
between cell lines and tumors is dominated by differ-
ences related mostly to the proliferative index of the
samples, with most cell lines growing at a much faster
rate than in vivo tumor cells [6–8,13,15]). However, in
the case of breast tumors, cell lines and tumors share
many aspects of their gene expression patterns that can
be related to the normal and pathological physiology
that distinguishes breast cell types in vivo. These gene
sets include 1) the basal epithelial cluster, 2) the lumi-
nal epithelial/ER+ cluster, 3) the ERBB2+ amplicon
cluster, 4) the proliferation cluster, and 5) the interferon
cluster [7,8]. Remarkably, the classes of tumors as de-
fined by gene expression, in part, are consistent with
current markers that are used for breast cancer strati-
fication and prognostication (e.g. ER status, ERBB2
status, proliferative index) [33].
In addition to re-identifying and elucidating tradi-
tional classes of tumors, gene expression patterns are
revealing novel subtypes of tumors that appear both bi-
ologically and clinically distinct. In the study by Sørlie
et al., the class of tumors distinguished by expression
of the basal epithelial signature, including expression
of cytokeratins 5 and 17, showed an outcome as poor
as ERBB2 over-expressing tumors and were as numer-
ous. Similarly, this study also identified a sub-group
of patients with ER-positive tumors, traditionally clas-
sified as having a good prognosis, that had very poor
outcomes [33]. The similarities and differences be-
tween cell lines and tumors should allow a much more
informed choice to be made about the appropriateness
of any given cell line model for a particular aspect of
tumor biology to be studied in vitro.
In addition to the dominant patterns of gene ex-
pression described in this review, there is tremen-
dous additional variation in gene expression pat-
terns in comparison between tumor subtypes (see
Supplementary Information Figures at http://genome-
www.stanford.edu/breast cancer/cell line review2001/).
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Gene expression studies of fifty to one hundred tumor
specimens likely does not have the power to identify all
of the inherent biologic diversity of tumors. It remains
to be determined whether one,a few, or tens to hundreds
of markers will be necessary to identify distinguish-
ing characteristics of tumors in the clinical setting. It
is likely that larger gene expression profiling studies,
and/or large in situ or immunohistochemistry studies
using candidate markers identified in microarray stud-
ies, will be necessary to distinguish all of the clini-
cally relevant variation in biology that can be exploited
to develop better patient management algorithms and
targeted drug strategies.
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